A message from The View from Jerusalem

Dear readers, I have recently begun writing a new weekly column in English for Hamodia, focusing on economic and business-related issues in Israel and in Europe. Going forward, I’ll be posting new additions on a weekly basis, along with the usual articles from the Jerusalem Post, which focus on global economic and financial issues. All The articles I’ve written for […]

» Read more

Israel-Turkey commercial links: a case study in political disruption of economic logic – an article at Knowledge@Wharton

Anyone following the Middle East via headlines in the mainstream media would know that diplomatic and political relations between Israel and Turkey have ruptured in recent years. It would therefore seem safe to assume that the economic and commercial links that once formed a central element of a generally close relationship between the two countries had shrivelled, under the impact […]

» Read more

A Curious Cut

This article appeared in the Economist magazine edition of September 5 and on the Economist site under the headline “Shekeled and bound”. The Bank of Israel, the country’s central bank, is seriously concerned about the state of the Israeli economy. That, it seems, is the rationale behind the decision by the bank’s Monetary Committee, at its monthly meeting on August […]

» Read more

What Does Israel’s Hadassah Crisis Mean for the Country’s Health Sector? – an article at Knowledge@Wharton

(Was Originally Published at Knowlegde@Wharton) The entire panoply of medical metaphors for dire situations could be effectively deployed to describe the current plight of Hadassah Hospital in Jerusalem, but any discussion of the crisis at Hadassah must perforce begin with a harsh legal term: Hadassah is the first hospital in Israel to be made subject to a stay of legal proceedings. […]

» Read more

Changing the Prescription for Israel’s Teva – an article at Knowledge@Wharton

(Was Originally Published at Knowlegde@Wharton) Changing the Prescription for Israel’s Teva On 11 February, when Erez Vigodman stepped into the corner office at Teva Pharmaceutical Industries, he didn’t come as a stranger to the company. He has been on the board since 2009 and this exposure should hold him in good stead. Vigodman has been brought in not as a […]

» Read more
1 3 4 5 6 7 8